
1. bioorg med chem lett. 2013 dec 15;23(24):6585-7. doi: 10.1016/j.bmcl.2013.10.060.
epub 2013 nov 6.

discovery irreversible hcv ns5b polymerase inhibitor.

zeng q(1), nair ag, rosenblum sb, huang hc, lesburg ca, jiang y, selyutin o, chan
ty, bennett f, chen kx, venkatraman s, sannigrahi m, velazquez f, duca js,
gavalas s, huang y, pu h, wang l, pinto p, vibulbhan b, agrawal s, ferrari e,
jiang ck, li c, hesk d, gesell j, sorota s, shih ny, njoroge fg, kozlowski ja.

author information: 
(1)merck research laboratories, 2015 galloping hill road, kenilworth, nj 07033,
usa.

the discovery lead compound 2e described. covalent binding hcv ns5b
polymerase enzyme investigated x-ray analysis. results of
distribution, metabolism pharmacokinetics reported. compound 2e was
demonstrated potent (replicon gt-1b ec50 = 0.003 μm), highly selective, and
safe vitro vivo assays.

copyright © 2013 elsevier ltd. rights reserved.

doi: 10.1016/j.bmcl.2013.10.060 
pmid: 24252545  [indexed medline]

